Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells

Vaccine

Volumn 25, Issue 19, 2007, Pages 3913-3921

  Angel, Juliette ^a,b,c   Chaperot, Laurence ^a,b,c   Molens, Jean Paul ^a,b,c   Mezin, Paulette ^d   Amacker, Mario ^e   Zurbriggen, Rinaldo ^e   Grichine, Alexei ^a   Plumas, Joël ^a,b,c  

^a INSERM   (France)

^b UNIV GRENOBLE ALPES   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d HÔPITAL MICHALLON   (France)

^e Pevion Biotech Ltd   (Switzerland)

Author keywords

Melanoma immunotherapy; PDC; Virosomes

Indexed keywords

CANCER ANTIBODY; CHIMERIC IMMUNOPOTENTIATING RECONSTITUTED INFLUENZA VIROSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; UNCLASSIFIED DRUG; VIROSOME;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOCYTOSIS; HUMAN; HUMAN CELL; INFLUENZA VIRUS; MELANOMA; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIROSOME MEDIATED ANTIGEN DELIVERY;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM PROTEINS; ORTHOMYXOVIRIDAE; VIROSOMES;

EID: 34247244107     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.101     Document Type: Article

References (30)

1. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 4 (2005) 296-306
2. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
3. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15 (1997) 821-850
4. Moron G., Dadaglio G., and Leclerc C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol 25 (2004) 92-97
5. Amacker M., Engler O., Kammer A.R., Vadrucci S., Oberholzer D., Cerny A., et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol 17 6 (2005) 695-704
6. Schumacher R., Amacker M., Neuhaus D., Rosenthal R., Groeper C., Heberer M., et al. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro. Vaccine 23 48-49 (2005) 5572-5582
7. Smith A.E., and Helenius A. How viruses enter animal cells. Science 304 5668 (2004) 237-242
8. Arkema A., Huckriede A., Schoen P., Wilschut J., and Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 18 14 (2000) 1327-1333
9. Bungener L., Huckriede A., de Mare A., de Vries-Idema J., Wilschut J., and Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23 10 (2005) 1232-1241
10. Hunziker I.P., Grabscheid B., Zurbriggen R., Gluck R., Pichler W.J., and Cerny A. In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. Int Immunol 14 6 (2002) 615-626
11. Amoscato A.A., Prenovitz D.A., and Lotze M.T. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 161 8 (1998) 4023-4032
12. Adamina M., Bolli M., Albo F., Cavazza A., Zajac P., Padovan E., et al. Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. Br J Cancer 90 1 (2004) 263-269
13. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284 5421 (1999) 1835-1837
14. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5 8 (1999) 919-923
15. Colonna M., Trinchieri G., and Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 5 12 (2004) 1219-1226
16. + T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood 101 9 (2003) 3520-3526
17. Chaperot L., Blum A., Manches O., Lui G., Angel J., Molens J.P., et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 176 1 (2006) 248-255
18. Chaperot L., Bendriss N., Manches O., Gressin R., Maynadie M., Trimoreau F., et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97 10 (2001) 3210-3217
19. + T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 258 1-2 (2001) 111-126
20. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194 6 (2001) 863-869
21. Jarrossay D., Napolitani G., Colonna M., Sallusto F., and Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31 11 (2001) 3388-3393
22. Gluck R., and Metcalfe I.C. New technology platforms in the development of vaccines for the future. Vaccine 20 Suppl 5 (2002) B10-B16
23. Esposito S., Marchisio P., Bosis S., Lambertini L., Claut L., Faelli N., et al. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 24 5 (2006) 629-635
24. Barchet W., Krug A., Cella M., Newby C., Fischer J.A., Dzionek A., et al. Dendritic cells respond to influenza virus through TLR7- and PKR-independent pathways. Eur J Immunol 35 1 (2005) 236-242
25. Bungener L., Serre K., Bijl L., Leserman L., Wilschut J., Daemen T., et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20 17-18 (2002) 2287-2295
26. Mestas J., and Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 172 5 (2004) 2731-2738
27. Urosevic M., Dummer R., Conrad C., Beyeler M., Laine E., Burg G., et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 97 15 (2005) 1143-1153
28. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 3 (2005) 739-746
29. Blanchet J.S., Valmori D., Dufau I., Ayyoub M., Nguyen C., Guillaume P., et al. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. J Immunol 167 10 (2001) 5852-5861
30. Stegmann T., Morselt H.W., Booy F.P., van Breemen J.F., Scherphof G., and Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J 6 9 (1987) 2651-2659